Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Imfinzi and Imjudo for Lung Cancer

US FDA Approves Imfinzi and Imjudo with Chemotherapy for Lung Cancer

Posted on November 14, 2022
Post Views: 379

Imfinzi and Imjudo for Lung CancerAstraZeneca’s Imfinzi in combination with Imjudo plus platinum-based chemotherapy has been approved for treatment of patients with Stage IV non-small cell lung cancer (NSCLC). The approval has been made by the Food and Drug Administration (FDA) based on the results from the POSEIDON Phase III trial. Melissa Johnson, MD, Director of Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, Tennessee, and a lead investigator in the POSEIDON Phase III trial, said: “Metastatic non-small cell lung cancer remains a significant treatment challenge because many patients’ tumors do not respond well to standard therapies, including checkpoint inhibitors. The approval of this dual immunotherapy regimen with chemotherapy introduces a new, generally well-tolerated treatment option for patients with this devastating disease and gives them the chance to benefit from the long-term survival advantage seen with CTLA-4 inhibition.”

The updated results from the POSEIDON Phase III trial have been published in the Journal of Clinical Oncology demonstrated sustained survival benefit and improved overall survival by 25% as comparison to chemotherapy alone. About 25% of patients treated with the combination were alive at three years as compared to 13.6% who were treated with chemotherapy alone. Imfinzi is the only approved immunotherapy and global standard of care in unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiation therapy. It is approved in the US and several other countries in combination with chemotherapy for treatment of locally advanced or metastatic biliary tract cancer based on the TOPAZ-1 Phase III trial.

The trial population included patients with either squamous, or non-squamous disease, and full range of PD-L1 expression levels.  The patients were treated with dose of Imfinzi, Imjudo with up to four cycles of chemotherapy every three weeks. This was then followed by maintenance treatment where doses were increased and pemetrexed maintenance treatment was allowed in all arms in patients with non-squamous disease if given during the induction phase.

The information shared in this blog is for educational purposes only. You should consult your healthcare professional for any medical needs.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,303)
  • Lung Cancer: Symptoms and Treatment (5,625)
  • What is Non-Small-Cell Lung Cancer? (5,531)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025
  • Lung Cancer Screening Is Beneficial For Non-Smokers As Well April 28, 2025
  • Understanding The Stage 0 Lung Cancer April 21, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
%d